Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer: A Phase 2 Nonrandomized Clinical Trial.

ABSTRACT:

Importance

Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with programmed cell death 1 protein (PD-1) inhibitors reported in CCGC merits further investigation.

Objective

To assess the clinical benefit of pembrolizumab in patients with previously treated advanced CCGC.

Design, setting, and participants

The PEACOCC trial is a single-arm multicenter phase 2 trial conducted at 5 UK centers investigating the clinical benefit and safety of pembrolizumab. PD-1 inhibitor-naive patients with histologically confirmed advanced CCGC, radiological disease progression following 1 or more prior courses of chemotherapy, and an Eastern Cooperative Oncology Group (ECOG)

SUBMITTER: Kristeleit R 

PROVIDER: S-EPMC11803509 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature